Bobak Azamian's financial journey with Tarsus Pharmaceuticals is notable. His stock holdings reached a staggering $51.88 million in January 2021, indicating a strong belief in the company’s potential. Since then, his wealth in Tarsus stock has fluctuated. By 2023, it...
Bobak Azamian's financial journey with Tarsus Pharmaceuticals is notable. His stock holdings reached a staggering $51.88 million in January 2021, indicating a strong belief in the company’s potential. Since then, his wealth in Tarsus stock has fluctuated. By 2023, it saw ups and downs, ending the year around $16 million. These fluctuations tell a story of a volatile market and a CEO closely tied to the company’s performance. His extensive stock ownership suggests not just financial investment, but also personal commitment, having held as much as 9% of Tarsus’s total stock. This commitment reflects his long-term vision for the company he helped to create.